Patterns of disease-modifying antirheumatic drug use, medical resource consumption, and cost among rheumatoid arthritis patients

Robert I. Griffiths, Miriam Bar-Din, Catherine MacLean, Erin M. Sullivan, Robert J. Herbert, Edward H. Yelin

Research output: Contribution to journalArticle

Abstract

We compared medical resource use and costs among rheumatoid arthritis (RA) patients receiving alternative disease-modifying antirheumatic drugs (DMARDs). The cohort study used data from a managed care organization. Health plan members who were prescribed DMARD therapy for at least 2 consecutive months, were age 18 years or older, had at least 6 months of DMARD-free enrollment prior to the first DMARD, and had a diagnosis of RA before or during the first month of DMARD were eligible. Median duration of initial DMARD therapy was 10 months overall: 11 months for hydroxychloroquine (n = 252), 15 months for methotrexate (n = 185), 5 months for sulfasalazine (n = 49), and 5 months for other mono/combination therapy (n = 85) (p <0.0001). The average monthly cost of care was $853, of which $294 (34%) was for RA-coded medial services. In multivariate analyses, monthly RA-coded costs varied significantly by initial DMARD. RA costs and duration of initial therapy varied significantly by initial DMARD.

Original languageEnglish (US)
Pages (from-to)92-104
Number of pages13
JournalTherapeutic Apheresis
Volume5
Issue number2
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Antirheumatic Agents
Rheumatoid Arthritis
Costs and Cost Analysis
Hydroxychloroquine
Drug Therapy
Sulfasalazine
Managed Care Programs
Methotrexate
Cohort Studies
Multivariate Analysis
Organizations
Health
Therapeutics

Keywords

  • Economics
  • Prosorba column therapy
  • Resource use
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Patterns of disease-modifying antirheumatic drug use, medical resource consumption, and cost among rheumatoid arthritis patients. / Griffiths, Robert I.; Bar-Din, Miriam; MacLean, Catherine; Sullivan, Erin M.; Herbert, Robert J.; Yelin, Edward H.

In: Therapeutic Apheresis, Vol. 5, No. 2, 2001, p. 92-104.

Research output: Contribution to journalArticle

Griffiths, Robert I. ; Bar-Din, Miriam ; MacLean, Catherine ; Sullivan, Erin M. ; Herbert, Robert J. ; Yelin, Edward H. / Patterns of disease-modifying antirheumatic drug use, medical resource consumption, and cost among rheumatoid arthritis patients. In: Therapeutic Apheresis. 2001 ; Vol. 5, No. 2. pp. 92-104.
@article{4e9b37f6f8ca422798c82005d78da2bd,
title = "Patterns of disease-modifying antirheumatic drug use, medical resource consumption, and cost among rheumatoid arthritis patients",
abstract = "We compared medical resource use and costs among rheumatoid arthritis (RA) patients receiving alternative disease-modifying antirheumatic drugs (DMARDs). The cohort study used data from a managed care organization. Health plan members who were prescribed DMARD therapy for at least 2 consecutive months, were age 18 years or older, had at least 6 months of DMARD-free enrollment prior to the first DMARD, and had a diagnosis of RA before or during the first month of DMARD were eligible. Median duration of initial DMARD therapy was 10 months overall: 11 months for hydroxychloroquine (n = 252), 15 months for methotrexate (n = 185), 5 months for sulfasalazine (n = 49), and 5 months for other mono/combination therapy (n = 85) (p <0.0001). The average monthly cost of care was $853, of which $294 (34{\%}) was for RA-coded medial services. In multivariate analyses, monthly RA-coded costs varied significantly by initial DMARD. RA costs and duration of initial therapy varied significantly by initial DMARD.",
keywords = "Economics, Prosorba column therapy, Resource use, Rheumatoid arthritis",
author = "Griffiths, {Robert I.} and Miriam Bar-Din and Catherine MacLean and Sullivan, {Erin M.} and Herbert, {Robert J.} and Yelin, {Edward H.}",
year = "2001",
doi = "10.1046/j.1526-0968.2001.005002092.x",
language = "English (US)",
volume = "5",
pages = "92--104",
journal = "Therapeutic Apheresis and Dialysis",
issn = "1744-9979",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Patterns of disease-modifying antirheumatic drug use, medical resource consumption, and cost among rheumatoid arthritis patients

AU - Griffiths, Robert I.

AU - Bar-Din, Miriam

AU - MacLean, Catherine

AU - Sullivan, Erin M.

AU - Herbert, Robert J.

AU - Yelin, Edward H.

PY - 2001

Y1 - 2001

N2 - We compared medical resource use and costs among rheumatoid arthritis (RA) patients receiving alternative disease-modifying antirheumatic drugs (DMARDs). The cohort study used data from a managed care organization. Health plan members who were prescribed DMARD therapy for at least 2 consecutive months, were age 18 years or older, had at least 6 months of DMARD-free enrollment prior to the first DMARD, and had a diagnosis of RA before or during the first month of DMARD were eligible. Median duration of initial DMARD therapy was 10 months overall: 11 months for hydroxychloroquine (n = 252), 15 months for methotrexate (n = 185), 5 months for sulfasalazine (n = 49), and 5 months for other mono/combination therapy (n = 85) (p <0.0001). The average monthly cost of care was $853, of which $294 (34%) was for RA-coded medial services. In multivariate analyses, monthly RA-coded costs varied significantly by initial DMARD. RA costs and duration of initial therapy varied significantly by initial DMARD.

AB - We compared medical resource use and costs among rheumatoid arthritis (RA) patients receiving alternative disease-modifying antirheumatic drugs (DMARDs). The cohort study used data from a managed care organization. Health plan members who were prescribed DMARD therapy for at least 2 consecutive months, were age 18 years or older, had at least 6 months of DMARD-free enrollment prior to the first DMARD, and had a diagnosis of RA before or during the first month of DMARD were eligible. Median duration of initial DMARD therapy was 10 months overall: 11 months for hydroxychloroquine (n = 252), 15 months for methotrexate (n = 185), 5 months for sulfasalazine (n = 49), and 5 months for other mono/combination therapy (n = 85) (p <0.0001). The average monthly cost of care was $853, of which $294 (34%) was for RA-coded medial services. In multivariate analyses, monthly RA-coded costs varied significantly by initial DMARD. RA costs and duration of initial therapy varied significantly by initial DMARD.

KW - Economics

KW - Prosorba column therapy

KW - Resource use

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=0035009013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035009013&partnerID=8YFLogxK

U2 - 10.1046/j.1526-0968.2001.005002092.x

DO - 10.1046/j.1526-0968.2001.005002092.x

M3 - Article

C2 - 11354305

AN - SCOPUS:0035009013

VL - 5

SP - 92

EP - 104

JO - Therapeutic Apheresis and Dialysis

JF - Therapeutic Apheresis and Dialysis

SN - 1744-9979

IS - 2

ER -